<DOC>
	<DOCNO>NCT00800943</DOCNO>
	<brief_summary>To evaluate whether CAMPATH-1H give patient CLL maximum response chemotherapy : ) eliminate minimal residual disease ( document flow cytometry ) patient achieve complete remission ( CR ) b ) convert partial remission complete remission . To evaluate time-to-progression patient accord pretreatment characteristic response status study entry . To evaluate whether CAMPATH-1H give patient CLL maximum response chemotherapy eliminate minimal residual disease determine real-time quantitative PCR .</brief_summary>
	<brief_title>Study Subcutaneous Campath-1H Patients With B-Cell CLL Residual Disease After Chemotherapy</brief_title>
	<detailed_description>Approximately 95 % case involve clonal proliferation B cell . Paraproteins , often IgM class , detect serum and/or urine patient CLL . Unique cell surface marker increasingly use diagnose disease , approximately 40 % patient , cytogenetic abnormality ( example , trisomy 12 ) find . Patients commonly present lymphocytosis , lymphadenopathy , splenomegaly symptom fatigue , weight loss , malaise . In advanced case anemia thrombocytopenia also occur . The clinical course CLL unpredictable , survival initial diagnosis vary 1 20 year ( 2 ) . In addition , subset patient indolent CLL whose absolute lymphocyte count le 30 x 109/L rarely die disease . CLL commonly stag accord 5-point system propose Rai ( Appendix B ) co-worker . While Rai stag relatively good predictor overall survival , predict prognosis individual patient .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Alemtuzumab</mesh_term>
	<criteria>Male female , least 18 year old . Signed informed consent . Zubrod performance status 0 , 1 , 2 ( Appendix C ) . Patients CLL , CLL/PLL PLL ( prolymphocytic ) achieve clinical complete remission NCIWG criterion chemotherapy , eg. , alkylating agent , fludarabine chemoimmunotherapy documentation residual disease immunophenotyping showing : ( ) residual population CD5 CD19 positive cell comprise ≥ 10 % marrow mononuclear cell population ; ( b ) residual population CD5 CD19 positive cell comprise &lt; 10 % marrow mononuclear cell Kappa/Lambda ratio &gt; 6 &lt; .33 . Patients CLL achieve partial remission ( PR ) nodular partial remission ( nPR ) NCIWG criterion chemotherapy . Creatinine , bilirubin , AST ALT alkaline phosphatase ≤2 x upper limit normal . Active infection . Past history anaphylaxis , follow exposure rat mouse derive CDRgrafted humanize monoclonal antibody . Less 2 month since prior chemotherapy . Previous treatment CAMPATH1H . Pregnant nursing woman . Patients corticosteroid . Uncontrolled autoimmune hemolytic anemia .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2008</verification_date>
	<keyword>Leukemia</keyword>
	<keyword>Chronic</keyword>
	<keyword>Chronic Lymphocytic Leukemia</keyword>
	<keyword>CAMPATH</keyword>
	<keyword>Alemtuzumab</keyword>
	<keyword>MabCampath</keyword>
	<keyword>Subcutaneous</keyword>
	<keyword>CLL</keyword>
	<keyword>C-CLL</keyword>
	<keyword>Residual</keyword>
</DOC>